Those with Acute Suicidal Ideation/Behavior, as classified by FDA-recognized scales, have a 33% chance of death (need a citation) within six months of onset. Although only 10% of the 30 million Americans suffering with depressive disorders have bipolar disorder, patients with bipolar depression may account for up to 60% of all depression-related suicides.¹ Bipolar Depression with ASIB also takes a dramatic economic toll on the U.S. healthcare system. Given the lack of suitable alternatives, the majority of patients are managed at the inpatient setting, which is costly to payers, patients, families, and employers. Pharmacological options are not effective for many patients and typically require more than three weeks to show effect. Other treatments, such as electro-convulsive therapy (ECT), are physically and emotionally draining and require extended hospitalization. Scientific findings  indicate that thoughts and impulses for suicide have biological underpinnings.² Emerging data suggests (need a citation) that suicidality in bipolar depression may be modulated by the brain’s NMDA receptor, providing a rationale for developing new therapies focused on this target.